Evidence map›Paper›PMID 40869221›Full record

SynthesisInternational journal of molecular sciences2025

Broad-Spectrum Antiviral Activity of Cyclophilin Inhibitors Against Coronaviruses: A Systematic Review.

Abdelazeem Elhabyan, Muhammad Usman S Khan, Aliaa Elhabyan, Rawan Abukhatwa, Hadia Uzair, Claudia Jimenez, Asmaa Elhabyan, Yee Lok Chan, Basma Shabana

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdelazeem ElhabyanInstitute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.
Muhammad Usman S KhanInstitute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.ORCID 0009-0005-0499-4019
Aliaa ElhabyanDepartment of Pathology, Faculty of Medicine, Tanta University, Tanta 31111, Egypt.
Rawan AbukhatwaFaculty of Medicine, Tanta University, Tanta 31111, Egypt.
Hadia UzairFaculty of Veterinary Science, University of Veterinary and Animal Sciences, Lahore 54000, Pakistan.
Claudia JimenezInstitute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.
Asmaa ElhabyanFaculty of Medicine, Tanta University, Tanta 31111, Egypt.
Yee Lok ChanDeanery of Biomedical Sciences, The University of Edinburgh, Edinburgh EH8 9YL, UK.
Basma ShabanaDermatology Department, Faculty of Medicine, Menoufia University, Shebeen El-Kom 6132720, Egypt.ORCID 0009-0006-9607-3993

Funding

UKRI BB/T00875X/1
6 · The paper itself

Abstract

Cyclophilins (Cyps), a family of peptidyl-prolyl isomerases, play essential roles in the life cycle of coronaviruses by interacting with viral proteins and modulating host immune responses. In this systematic review, we examined cell culture, animal model, and clinical studies assessing the anti-viral efficacy of cyclosporine A (CsA, PubChem CID: 5284373) and its non-immunosuppressive derivatives against coronaviruses. CsA demonstrated robust anti-viral activity in vitro across a broad range of coronaviruses, including but not limited to HCoV-229E, SARS-CoV, MERS-CoV, and SARS-CoV-2, with potent EC

Indexed as

Antiviral AgentsCoronavirusCyclophilinsCyclosporineAnimalsCOVID-19COVID-19 Drug TreatmentHumansSARS-CoV-2Virus ReplicationAntiviral AgentsCyclophilinsCyclosporinealisporivirbroad-spectrum anti-viralcoronavirusescyclophilin inhibitorscyclosporine AHCoV-229EMERS-CoVSARS-CoVSARS-CoV-2viral replication

Identifiers

PMID40869221
PMCPMC12386573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.